Bristol-Myers Squibb Co. is paying Aslan Pharmaceuticals Pte. Ltd. $10m upfront to reacquire at an early stage the Asian rights to a first-in-class oncology molecule it originally licensed to the Singapore-based oncology venture back in 2011.
ASLAN will also be eligible for development and regulatory milestones "in excess of" a further $50m, plus royalties on BMS' future worldwide sales of the drug, ASLAN002 (also known as BMS777607), while the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?